8-K: Coherus BioSciences Reports Q1 2025 Financial Results and Business Update

Coherus BioSciences completes strategic transformation to innovative oncology, reporting Q1 2025 financial results with a focus on LOQTORZI and pipeline advancement.

Summary

• Coherus BioSciences reported its financial results for the first quarter of 2025.
• The company completed its strategic transformation to focus on innovative oncology in Q2 2025.
• LOQTORZI net revenue was $7.3 million in Q1 2025.
• UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025.
• The company presented positive Phase 1b data for CHS-114 in head and neck cancer at the 2025 AACR Annual Meeting.
• Enrollment is ongoing in the Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data expected in 1H 2026.
• The UDENYCA divestiture was completed in April 2025 for up to $558.4 million.
• Net loss from continuing operations for Q1 2025 was $47.4 million, or $(0.41) per share.
• Cash and cash equivalents totaled $82.4 million as of March 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, there are positive developments such as growing LOQTORZI sales, positive clinical data for CHS-114, and the completion of the UDENYCA divestiture. The strategic shift towards oncology and debt reduction efforts are also encouraging.

Positives

• LOQTORZI sales are growing, with a 15% increase in patient demand compared to the previous quarter.
• Positive early clinical data from the CHS-114 Phase 1 trial supports further evaluation in combination therapies.
• The UDENYCA divestiture provides a significant upfront payment and potential milestone payments, strengthening the company's financial position.
• The company is reducing debt by repurchasing convertible notes.
• The overall response rate (ORR) increased to 38% compared to 27% initially announced, and complete responses per RECIST v1.1 increased to 17.2% compared to 10.3% previously announced and the initial assessment of 0% in the Phase 2 trial of casdozokitug/atezolizumab/bevacizumab in 1L HCC.

Negatives

• The company reported a net loss from continuing operations of $47.4 million for Q1 2025.
• Cash and cash equivalents decreased from $126.0 million at the end of 2024 to $82.4 million as of March 31, 2025.
• Net income (loss) from discontinued operations, net of tax was a net loss of $9.2 million, or $(0.08) per share on a diluted basis, for first quarter of 2025 compared to net income of $170.9 million, or $1.52 per share on a diluted basis, for the same period in 2024.

Risks

• The company faces risks inherent in the clinical drug development process.
• There are risks related to existing and potential collaboration partners.
• The company faces risks related to its competitive position.
• The company faces risks related to the regulatory approval process.
• The company faces the risk of FDA review issues.
• The company faces the risk that it is unable to complete commercial transactions.
• The company faces the risks and uncertainties of possible litigation.

Future Outlook

Coherus plans to maximize LOQTORZI revenues, advance novel immuno-oncology candidates in combination with LOQTORZI to key data milestones in 2026, and progress label expanding indications for LOQTORZI in novel combinations. The company is also pursuing additional partnerships evaluating LOQTORZI with novel promising cancer agents in 2025.

Management Comments

• The completion of the UDENYCA divestiture in April positions us to focus on our innovative oncology portfolio, said Denny Lanfear, Coherus Chairman and Chief Executive Officer.
• This includes maximizing LOQTORZI revenues, advancing our novel immuno-oncology candidates in combination with LOQTORZI to key data milestones in 2026, and progressing label expanding indications for LOQTORZI in novel combinations.
• At AACR last month, we reported promising early clinical data from our ongoing Phase 1 clinical trial evaluating CHS-114, which supports continued evaluation of CHS-114 in combination with other therapies, including toripalimab in HNSCC, stated Theresa LaValle, Ph.D., Coherus Chief Scientific and Development Officer.
• We believe CHS-114 has the potential to treat many solid tumors outside of head and neck cancer, including other large, underserved immuno-oncology indications, such as colorectal cancer.

Industry Context

Coherus's strategic shift towards innovative oncology and focus on LOQTORZI aligns with the industry trend of developing targeted immunotherapies for cancer treatment. The company's pipeline candidates, such as CHS-114 and casdozokitug, address unmet needs in specific cancer types, positioning Coherus in a competitive landscape with other companies developing similar therapies.

Comparison to Industry Standards

• LOQTORZI's designation as the only treatment with Preferred status in NPC by the NCCN highlights its competitive advantage in this specific indication.
• The reported overall response rate (ORR) of 38% in the Phase 2 trial of casdozokitug/atezolizumab/bevacizumab in 1L HCC is comparable to other combination therapies in this setting, such as atezolizumab plus bevacizumab, which has shown ORRs in the range of 27-36% in clinical trials.
• Companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo) are major players in the PD-1 inhibitor market, and Coherus aims to differentiate LOQTORZI through novel combinations and targeted indications.

Stakeholder Impact

• Shareholders: The strategic shift towards oncology and potential for LOQTORZI growth could positively impact shareholder value, but the reported net loss may raise concerns.
• Employees: The focus on innovative oncology may lead to new opportunities for employees in research and development.
• Customers (Patients): Advancements in the pipeline and expanded indications for LOQTORZI could provide new treatment options for cancer patients.
• Suppliers: The divestiture of UDENYCA may impact suppliers associated with that franchise.
• Creditors: Debt reduction efforts through convertible note repurchases could improve the company's creditworthiness.

Next Steps

• Maximize LOQTORZI revenues.
• Advance novel immuno-oncology candidates in combination with LOQTORZI to key data milestones in 2026.
• Progress label expanding indications for LOQTORZI in novel combinations.
• Pursue additional partnerships evaluating LOQTORZI with novel promising cancer agents in 2025.
• Repurchase the remaining approximately $60 million aggregate principal amount of 2026 Convertible Notes on May 15, 2025.

Key Dates

Keywords

LOQTORZI, Coherus BioSciences, Financial Results, Oncology, CHS-114, UDENYCA, Casdozokitug, Toripalimab, Q1 2025, Immunotherapy